Nicola Gale

In a groundbreaking announcement, a Food and Drug Administration (FDA) advisory panel gave their unanimous recommendation in April 2018 for the approval of Epidiolex, a cannabis-derived product shown to be effective for the treatment of two forms of treatment-resistant childhood epilepsies.

Orkambi and Kalydeco are members of a new generation of medications that are making history for people living with Cystic Fibrosis. These treatments focus on improving underlying lung function rather than simply delaying its decline...